Ron Squarer - 16 Jan 2024 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Director
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
DCPH
Transactions as of
16 Jan 2024
Net transactions value
+$50,004
Form type
4
Filing time
18 Jan 2024, 16:15:10 UTC
Previous filing
05 Jun 2025
Next filing
10 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $50,004 +4,727 $10.58 4,727 16 Jan 2024 Common Stock 4,727 $14.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2024 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.